Scorpion Venom and Epilepsy

The fourth most common neurological disease is epilepsy, a seizure disorder. It affects 1 in 26 people and can happen in any age group. Seizures are often unpredictable, making it difficult to manage.  While some causes of epilepsy are related to brain injury, most are of unknown origin.  A rare form of epilepsy is Dravet Syndrome (DS).  DS is lifelong and appears in the first year of life and typically causes developmental delays, negatively impacts quality of life, and increases risk of Sudden Unexpected Death in Epilepsy (SUDEP).  Unfortunately, it does not respond well to current anti-seizure medications. Two new treatments, Epidiolex and Stiripentol, have been FDA approved in 2018 and offer some hope.1 Mutations in the SCN1A gene appear in 80% of those with DS and abnormal function of the Nav1.1 protein negatively affect neuronal activity.2

https://www.pepnet.com/res/uploads/media//scorpion_and_brain.jpg

While currently available sodium channel blocking medications can make the condition worse, recent research indicates that specific blocking of Nav1.1 channel inactivation in mice offers relief from seizures in DS.   A new publication in ACS Pharmacology & Translational Science looks at novel scorpion venom components, Hj1a and Hj2a, which delay Nav1.1 inactivation.  The authors previously identified a tarantula toxin, a knottin called Hm1a, which has a high specificity for Nav1.1 activation.  Hj1a and Hj2a are members of the CSαß toxin family and are dual modulatory, with both α- and ß-toxin activity. Unfortunately, while the scorpion venoms lack the selectivity to Nav1.1, they can, however, be useful tools for Nav1.1 channel investigation and for the development of an analog that could offer treatment hope in the future.3

References:

  1. Epilepsy Foundation. (n.d.) What is Epilepsy. https://www.epilepsy.com/learn/about-epilepsy-basics/what-epilepsy
  2. Dravet Syndrome Foundation. (n.d.) What is Dravet Syndrome? https://www.dravetfoundation.org/dsf-funded-research/
  3. C.Y. Chow, et al., ACS Pharmacology & Translational Science, 3, 119 (2020).
Industry News , Biologically Active Peptides , Neuroscience

Denise Karounos

See all articles from Denise Karounos

Denise Karounos joined Peptides International in October 2016. After completing her BS in chemistry from West Virginia University, she spent time as an organic chemist at Bachem Bioscience synthesizing peptides and amino acid derivatives. Denise has experience with both solid and solution-phase peptide synthesis, and has worked under both research and cGMP settings. After completion of her MBA at Saint Joseph’s University, Denise transitioned into product management of peptides and amino acid derivatives. Denise has spent her time at PI focusing on both sales and marketing, including quoting, product management, market research and sales analysis, generating technical marketing content, and attending industry conferences.